Hyloris is eligible to receive a share of any product-related revenues incl. license fees, milestones & royalties
Maxigesic IV is a novel, dual mode-of-action non-opioid pain treatment delivered through IV infusions while 2023 is the anticipated year for the initial commercial launches
The P-III trial results showed that compared to ibuprofen IV or paracetamol IV alone, Maxigesic IV was found to be well-tolerated, had a faster onset of action, provided greater pain relief, and provided the potential to reduce the use of opioids. The drug’s effectiveness and safety have been proven in additional studies in a larger population over a longer treatment period
Ref: Globenewswire | Image: Hyloris
Related News:- CardioRenal Systems’ RenalGuard Therapy Device Receives the US FDA’s Breakthrough Device Designation for Cardiac Surgery Associated AKI
